Company Filing History:
1 out of 1 
1 out of 1,292 
Years Active: 2019
Title: Janet Chusainow: Innovator in Retroviral Research
Introduction
Janet Chusainow is a prominent inventor based in Dresden, Germany. She has made significant contributions to the field of virology, particularly in the development of methods for combating retroviral infections. Her innovative work has led to the creation of a patented technology that holds promise for the treatment and prevention of diseases caused by retroviruses.
Latest Patents
Janet Chusainow holds a patent for a "Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains." This invention relates to a method for preparing an expression vector that encodes a tailored recombinase. This recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA from various retrovirus strains. The patent also covers the expression vector, cells transfected with it, and pharmaceutical compositions that include the expression vector, cells, and/or recombinase. These pharmaceutical compositions are particularly useful in the treatment and prevention of retrovirus infections, including those caused by multiple strains of HIV.
Career Highlights
Throughout her career, Janet has worked with several esteemed research institutions. She has been associated with the Heinrich Pette Institute, Leibniz Institute for Experimental Virology, and the Max Planck Society for the Advancement of Science. Her work in these institutions has allowed her to advance her research and contribute to significant scientific discoveries.
Collaborations
Janet has collaborated with notable colleagues in her field, including Joachim Hauber and Jan Chemnitz. These collaborations have enriched her research and expanded the impact of her innovations in virology.
Conclusion
Janet Chusainow is a trailblazer in the field of retroviral research, with a patented invention that has the potential to change the landscape of treatment for retroviral infections. Her contributions to science and her collaborations with other experts highlight her commitment to advancing medical research.